![BioGaia, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1d12ad0a-8185-425d-8445-1ba5281aa3a0.png)
BioGaia
126 SEK +1.04%2 investors are following this company
BioGaia is a biotechnology company. The company develops, markets and sells probiotic products. The products are mainly based on the bacterium Lactobacillus, which has probiotic effects. Today, the company's products are sold around the global market. Research and development are conducted via the company's external network of research institutions and clinics. The head office is located in Stockholm.
Revenue
-
EBIT %
-
P/E
34.81
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BIOG B
Daily low / high price
123.4 / 127.5
SEK
Market cap
12.72B SEK
Turnover
5.64M SEK
Volume
45K
Latest videos
Financial calendar
Interim report
22.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
EQT | 11.1 % | 8.3 % |
Fjärde AP-fonden | 7.7 % | 5.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![BioGaia, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/1d12ad0a-8185-425d-8445-1ba5281aa3a0.png)
BioGaia AB: Interim Management Statement January - June 2024
Annual General Meeting of BioGaia
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
![BioGaia, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/196bca62-f1be-492d-ae0d-e2aa03250d46.png)
BioGaia, Audiocast with teleconference, Q1, 2024
BioGaia AB: Interim Management Statement January - March 2024
Notice to attend the Annual General Meeting of BioGaia AB (publ)
BioGaia Annual and Sustainability Report 2023 published
![BioGaia, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/80dcd3f2-6039-493c-b556-73d7392b8300.png)
BioGaia, Audiocast with teleconference, Q4, 2023
BioGaia AB: Year-end report January - December 2023
![BioGaia, Audiocast with teleconference, Q3, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/3f7336b5-794a-4485-8f6f-90caae933d69.png)
BioGaia, Audiocast with teleconference, Q3, 2023
BioGaia AB: Interim report third quarter January - September 2023
BioGaia AB's Nomination Committee for the 2024 Annual General Meeting
BioGaia's results for the third quarter to exceed market expectations
Invitation to media and analyst briefing for BioGaia Q3 2023 report
Theresa Agnew commences her role as CEO of BioGaia
Introducing BioGaia Prodentis KIDS in Sweden
BioGaia and University of Gothenburg reach an important milestone towards next-generation probiotics
BioGaia appoints Theresa Agnew as new CEO
![BioGaia, Audiocast with teleconference, Q2, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/12f84f2e-e6c1-4944-a0c6-6847070fd7d3.png)